4th Quarter - Report — CEPHEID for CEPHEID (2008)

Firm

CEPHEID

Client

CEPHEID

Income

—

Expenses

$60,000

Expense method

A: Lobbying Disclosure Act definitions

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

S 2278/HR 4214, Community and Healthcare-Associated Infections Reduction Act S 2312/HR 3697, Strategies to Address Antimicrobial Resistance Act S 2525, MRSA Infection Prevention and Patient Protection Act HR 1174, Healthy Hospital Act

Lobbyist	Covered position, as disclosed
HALLIE CHRISTINE LEWIS	Director, Government Relations
MICHELE M SCHOONMAKER	Director, Government Affairs

Contacted: Natl Institutes of Health (NIH); Centers For Medicare and Medicaid Services (CMS); Centers For Disease Control & Prevention (CDC); SENATE; Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA)

Bills named: H.R. 4214 (110th), H.R. 3697 (110th), H.R. 1174 (110th)

Medical/Disease Research/Clinical Labs MED

Lobbyist	Covered position, as disclosed
HALLIE CHRISTINE LEWIS	Manager, Government Relations
MICHELE M SCHOONMAKER	Director, Government Affairs

Contacted: Health & Human Services, Dept of (HHS); Natl Institutes of Health (NIH); SENATE; Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Centers For Disease Control & Prevention (CDC); Centers For Medicare and Medicaid Services (CMS)

Bills named: H.R. 4214 (110th), H.R. 3697 (110th), H.R. 1174 (110th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.